Inhibition of STAT3 Signaling Induces Apoptosis and Suppresses Growth of Lung Cancer: Good and Bad

Overview

Journal Lab Anim Res

Date 2020 Apr 8

PMID 32257917

Citations 15

Authors

Ju-Hee Kang

Yeong-Su Jang

Ha Jung Lee

Chang-Yong Lee

Dong Yun Shin

Seung Hyun Oh

Affiliations

Soon will be listed here.

Abstract

Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For many cancers, elevated levels of STAT3 signaling have been associated with a poor prognosis and the development of chemotherapy resistance. In this study, we investigated the inhibitory effects of a novel small-molecule inhibitor of STAT3, STX-0119, on the cell viability and survival of human lung cancer cells. STX-0119 inhibited activated STAT3 and the expression of STAT3-regulated oncoproteins such as c-Myc, cyclin D1, and survivin in lung cancer cells. STX-0119 also decreased the amount of STAT3 in the nuclear fraction as well as induced apoptosis of these lung cancer cell lines as evidenced by increases in apoptotic cells (Annexin V positive) and poly (ADP-ribose) polymerase (PARP) cleavage. The efficacy of STX-0119 in a mouse xenograft model was confirmed. However, a hematological side effect, which had not been previously reported, was observed. The level of white blood cells was significantly lowered when treated at the dose at which STX-0119 alone showed a significant tumor-suppressive effect. In conclusion, we suggest that STX-0119 may be a potent therapeutic agent against lung cancer. Consideration of the side effect suggests, it is necessary to study whether low-dose STX-0119 is effective for lung treatment with a combination of classic lung cancer therapeutics.

Citing Articles

Overexpression of IL-6 and STAT3 may provide new insights into ovine pulmonary adenocarcinoma development.

Toma C, Popa R, Ciobanu L, Baldea I, Amorim I, Bochynska D BMC Vet Res. 2025; 21(1):29.

PMID: 39833798 PMC: 11744984. DOI: 10.1186/s12917-024-04429-6.

The Suppression of Signal Transducer and Activator of Transcription-3 in A549 human Lung Carcinoma Cells Induced by Marine Sponge .

Hadisaputri Y, Nurhaniefah A, Mutakin M, Hendriani R, Rezano A, Sopyan I J Exp Pharmacol. 2025; 17():15-25.

PMID: 39816162 PMC: 11734514. DOI: 10.2147/JEP.S494158.

TTI-101 targets STAT3/c-Myc signaling pathway to suppress cervical cancer progression: an integrated experimental and computational analysis.

Li Y, Dong Y Cancer Cell Int. 2024; 24(1):286.

PMID: 39135042 PMC: 11320917. DOI: 10.1186/s12935-024-03463-6.

Targeting STAT3 Enzyme for Cancer Treatment.

Arun S, Patel P, Lakshmanan K, Rajangopal K, Swaminathan G, Byran G Mini Rev Med Chem. 2024; 24(13):1252-1261.

PMID: 38299278 DOI: 10.2174/0113895575254012231024062619.

Neuroprotective Effects of in a Chronic Neuroinflammatory Disease Model.

Jo S, Yang H, Jeong K, Lee H, Hong E Nutrients. 2023; 15(8).

PMID: 37111229 PMC: 10142528. DOI: 10.3390/nu15082007.

References

Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12(4):237-51. PMC: 3967236. DOI: 10.1038/nrc3237. View

Matsuno K, Masuda Y, Uehara Y, Sato H, Muroya A, Takahashi O . Identification of a New Series of STAT3 Inhibitors by Virtual Screening. ACS Med Chem Lett. 2014; 1(8):371-5. PMC: 4007973. DOI: 10.1021/ml1000273. View

Bollrath J, Phesse T, von Burstin V, Putoczki T, Bennecke M, Bateman T . gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009; 15(2):91-102. DOI: 10.1016/j.ccr.2009.01.002. View

Bournazou E, Bromberg J . Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT. 2013; 2(2):e23828. PMC: 3710325. DOI: 10.4161/jkst.23828. View

Lee H, Jeong A, Ye S . Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep. 2019; 52(7):415-423. PMC: 6675244. View

Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G . Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1):105-15. DOI: 10.1016/s1074-7613(00)80011-4. View

Yu H, Kortylewski M, Pardoll D . Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2006; 7(1):41-51. DOI: 10.1038/nri1995. View

Furtek S, Backos D, Matheson C, Reigan P . Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol. 2016; 11(2):308-18. DOI: 10.1021/acschembio.5b00945. View

10.

Leeman R, Lui V, Grandis J . STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther. 2006; 6(3):231-41. DOI: 10.1517/14712598.6.3.231. View

11.

Ashizawa T, Miyata H, Ishii H, Oshita C, Matsuno K, Masuda Y . Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol. 2011; 38(5):1245-52. DOI: 10.3892/ijo.2011.957. View

12.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A . Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol. 2013; 43(1):219-27. DOI: 10.3892/ijo.2013.1916. View

13.

Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H . Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009; 69(6):2506-13. PMC: 2664264. DOI: 10.1158/0008-5472.CAN-08-4323. View

14.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

15.

Crino L, Weder W, Van Meerbeeck J, Felip E . Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v103-15. DOI: 10.1093/annonc/mdq207. View

16.

Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H . The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. Immunol Lett. 2017; 190:20-25. DOI: 10.1016/j.imlet.2017.07.005. View

17.

Xiong H, Du W, Wang J, Wang Y, Tang J, Hong J . Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berl). 2012; 90(9):1037-46. DOI: 10.1007/s00109-012-0869-0. View

18.

Groner B, Lucks P, Borghouts C . The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol. 2008; 19(4):341-50. DOI: 10.1016/j.semcdb.2008.06.005. View

19.

Huang X, Meng B, Iqbal J, Ding B, Perry A, Cao W . Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2013; 31(36):4520-8. PMC: 3871513. DOI: 10.1200/JCO.2012.45.6004. View

20.

Hahn K, Jung H, Yoo D, Kim J, Kim Y, Jo Y . Immunohistochemical localization of glucose transporter 1 and 3 in the scrotal and abdominal testes of a dog. Lab Anim Res. 2017; 33(2):114-118. PMC: 5527136. DOI: 10.5625/lar.2017.33.2.114. View